Justin Zelin Analyst Performance

Director, Biotechnology Equity Research Analyst at BTIG Research

Justin Zelin is a stock analyst at BTIG Research focused in the medical sector, covering 9 publicly traded companies. Over the past year, Justin Zelin has issued 11 stock ratings, including and buy recommendations. While full access to Justin Zelin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Justin Zelin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 17 Last 4 Years
Buy Recommendations: 100.00% 17 Buy Ratings
Companies Covered: 9 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	100.0%	17 ratings
Hold	0.0%	0 ratings
Sell	0.0%	0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

Best Call
0000.0%
BLU
Sep 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
MBIO
Jun 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	88.9% of companies on NASDAQ	8 companies
TSE	11.1% of companies on TSE	1 company

Justin Zelin, an analyst at BTIG Research, currently covers 9 companies listed on NASDAQ and TSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 8 companies	88.9%
	Finance 1 company	11.1%

Justin Zelin of BTIG Research specializes in stock coverage within the Medical sector, with additional focus on Finance companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 7 companies	77.8%
FIN - MISC SVCS 1 company	11.1%
BIOTECHNOLOGY 1 company	11.1%

About Justin Zelin

Justin Zelin is a Director and BTIG Biotechnology Analyst, specializing in cell therapy, targeted oncology, immunology and auto-immune disease therapeutics. Prior to BTIG, Mr. Zelin was a Biotech Equity Research Analyst at B. Riley Securities. Previously, he held biotech equity research associate roles at Canaccord Genuity and SVB Leerink. Earlier in his career, Mr. Zelin worked in both academic and industry labs including Agenus, Harvard University and Brigham and Women’s Hospital. He was also a member of Harvard University’s teaching staff for more than five years. Mr. Zelin earned a master’s degree in biotechnology and a bachelor’s degree in biology from Harvard University.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
IMAB I-Mab	10/24/2025	Reiterated Rating	$4.39	$9.00	Buy
IDYA IDEAYA Biosciences	10/21/2025	Reiterated Rating	$30.51	$62.00	Buy
IMAB I-Mab	10/17/2025	Boost Price Target	$5.85	$9.00	Buy
CAN Canaan	10/14/2025	Reiterated Rating	$1.52	$8.00	Buy
JSPR Jasper Therapeutics	9/22/2025	Lower Price Target	$2.50	$7.00	Buy
VKTX Viking Therapeutics	9/22/2025	Reiterated Rating	$26.58	$125.00	Buy
SNDX Syndax Pharmaceuticals	9/19/2025	Reiterated Rating	$14.77	$56.00	Buy
IMAB I-Mab	9/9/2025	Initiated Coverage	$4.27	$7.00	Buy
VSTM Verastem	9/9/2025	Reiterated Rating	$10.23	$20.00	Buy
SNDX Syndax Pharmaceuticals	8/5/2025	Boost Price Target	$12.23	$56.00	Buy
JSPR Jasper Therapeutics	7/7/2025	Lower Price Target	$3.04	$20.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.